BR0110548A - Composto, processo para a preparação do mesmo, composição farmacêutica, método de tratamento de distúrbios mediados pelo receptor de neuropeptìdio y5 em um animal de sangue quente, método de tratamento de distúrbios da alimentação em um animal de sangue quente, método para promover perda de peso em um animal de sangue quente, e, uso de um composto ou de um seu sal, prodroga ou solvato farmacêuticamente aceitável - Google Patents
Composto, processo para a preparação do mesmo, composição farmacêutica, método de tratamento de distúrbios mediados pelo receptor de neuropeptìdio y5 em um animal de sangue quente, método de tratamento de distúrbios da alimentação em um animal de sangue quente, método para promover perda de peso em um animal de sangue quente, e, uso de um composto ou de um seu sal, prodroga ou solvato farmacêuticamente aceitávelInfo
- Publication number
- BR0110548A BR0110548A BR0110548-5A BR0110548A BR0110548A BR 0110548 A BR0110548 A BR 0110548A BR 0110548 A BR0110548 A BR 0110548A BR 0110548 A BR0110548 A BR 0110548A
- Authority
- BR
- Brazil
- Prior art keywords
- warm
- blooded animal
- compound
- treating
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/76—Dibenzothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
"COMPOSTO, PROCESSO PARA A PREPARAçãO DO MESMO, COMPOSIçãO FARMACêUTICA, MéTODO DE TRATAMENTO DE DISTúRBIOS MEDIADOS PELO RECEPTOR DE NEUROPEPTìDIO Y5 EM UM ANIMAL DE SANGUE QUENTE, MéTODO DE TRATAMENTO DE DISTúRBIOS DA ALIMENTAçãO EM UM DE SANGUE QUENTE, MéTODO PARA PROMOVER PERDA DE PESO EM UM DE SANGUE QUENTE, E, USO DE UM COMPOSTO OU DE UM SEU SAL, PRODROGA OU SOLVATO FARMACEUTICAMENTE ACEITáVEL". Descreve-se compostos da fórmula (I), em que X é um grupo da fórmula (A) ou (B) e R^ 1^,R^ 2^, R^ 3^, R^ 4^, x, y e z são definidos aqui. Descreve-se também processos para sua preparação e seu uso no tratamento de distúrbios mediados pelo receptor de neuropeptídio Y5 e m um animal de sangue quente, como um ser humano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0010757.3A GB0010757D0 (en) | 2000-05-05 | 2000-05-05 | Chemical compounds |
PCT/GB2001/001899 WO2001085714A1 (en) | 2000-05-05 | 2001-05-01 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0110548A true BR0110548A (pt) | 2003-04-01 |
Family
ID=9890945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0110548-5A BR0110548A (pt) | 2000-05-05 | 2001-05-01 | Composto, processo para a preparação do mesmo, composição farmacêutica, método de tratamento de distúrbios mediados pelo receptor de neuropeptìdio y5 em um animal de sangue quente, método de tratamento de distúrbios da alimentação em um animal de sangue quente, método para promover perda de peso em um animal de sangue quente, e, uso de um composto ou de um seu sal, prodroga ou solvato farmacêuticamente aceitável |
Country Status (16)
Country | Link |
---|---|
US (2) | US6967216B2 (pt) |
EP (1) | EP1278739A1 (pt) |
JP (1) | JP2003532723A (pt) |
KR (1) | KR20020093975A (pt) |
CN (1) | CN1440401A (pt) |
AR (1) | AR028414A1 (pt) |
AU (1) | AU2001252372A1 (pt) |
BR (1) | BR0110548A (pt) |
CA (1) | CA2406634A1 (pt) |
GB (1) | GB0010757D0 (pt) |
IL (1) | IL152230A0 (pt) |
MX (1) | MXPA02010563A (pt) |
NO (1) | NO20025286D0 (pt) |
NZ (1) | NZ522188A (pt) |
WO (1) | WO2001085714A1 (pt) |
ZA (1) | ZA200208674B (pt) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115741B2 (en) * | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
JP4330996B2 (ja) * | 2001-12-04 | 2009-09-16 | シェーリング コーポレイション | 肥満の処置のためのmchアンタゴニストとしてのn−アリール−n’−アリールシクロアルキル−尿素−誘導体 |
CA2471620A1 (en) * | 2001-12-31 | 2003-07-24 | Actelion Pharmaceuticals Ltd | Pyrrolidone carboxamides |
US7067549B2 (en) | 2001-12-31 | 2006-06-27 | Actelion Pharmaceuticals Ag | Pyrrolidone carboxamides |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
JP4866610B2 (ja) | 2003-08-18 | 2012-02-01 | 富士フイルムファインケミカルズ株式会社 | ピリジルテトラヒドロピリジン類およびピリジルピペリジン類 |
JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Msd株式会社 | 新規ピペリジン誘導体 |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
MX2007003318A (es) * | 2004-09-20 | 2007-05-18 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como agentes terapeuticos. |
US7767677B2 (en) | 2004-09-20 | 2010-08-03 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
AU2005286728A1 (en) * | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase |
JP4958785B2 (ja) | 2004-09-20 | 2012-06-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体およびステアロイル−CoAデサチュラーゼインヒビターとしてのそれらの使用 |
AR051094A1 (es) * | 2004-09-20 | 2006-12-20 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
CN101084211A (zh) * | 2004-09-20 | 2007-12-05 | 泽农医药公司 | 杂环衍生物及其作为治疗剂的用途 |
AU2005286648A1 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors |
EP1827438B2 (en) * | 2004-09-20 | 2014-12-10 | Xenon Pharmaceuticals Inc. | Piperazin derivatives for inhibiting human stearoyl-coa-desaturase |
ES2325773T5 (es) | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals, Llc. | Tratamiento de la obesidad y de los trastornos relacionados |
US20090014363A1 (en) * | 2005-02-07 | 2009-01-15 | Recyclebank Llc | Drop-off recycling system and method thereof |
WO2007022123A2 (en) | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US8138206B2 (en) | 2005-05-30 | 2012-03-20 | Msd. K.K. | Piperidine derivative |
WO2007130075A1 (en) | 2005-06-03 | 2007-11-15 | Xenon Pharmaceuticals Inc. | Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors |
CA2618112A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
EP2330125A3 (en) | 2005-08-11 | 2012-12-12 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
EP1921065B1 (en) | 2005-08-24 | 2010-10-20 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
CN101277960A (zh) | 2005-09-29 | 2008-10-01 | 默克公司 | 作为黑皮质素-4受体调节剂的酰化螺哌啶衍生物 |
WO2007048027A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
AU2006307046A1 (en) | 2005-10-27 | 2007-05-03 | Msd K.K. | Novel benzoxathiin derivative |
JP4371164B2 (ja) | 2005-11-10 | 2009-11-25 | 萬有製薬株式会社 | アザ置換スピロ誘導体 |
CA2664113C (en) | 2006-09-22 | 2013-05-28 | Merck & Co., Inc. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
EP2072519A4 (en) | 2006-09-28 | 2009-10-21 | Banyu Pharma Co Ltd | DIARYLKETIMINDERIVAT |
US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2178534A4 (en) * | 2007-07-17 | 2011-03-30 | Merck Sharp & Dohme | SOLUBLE EPOXY HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND PROCESSING METHODS |
US20110015181A1 (en) | 2008-03-06 | 2011-01-20 | Makoto Ando | Alkylaminopyridine derivative |
CN101981025A (zh) | 2008-03-28 | 2011-02-23 | 万有制药株式会社 | 具有黑色素浓缩激素受体拮抗作用的二芳基甲基酰胺衍生物 |
AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010013595A1 (ja) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | 5員-5員又は5員-6員縮環シクロアルキルアミン誘導体 |
MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
PE20110852A1 (es) | 2008-10-30 | 2011-11-25 | Merck Sharp & Dohme | Antagonistas del receptor de orexina de isonicotinamida |
EP2362731B1 (en) | 2008-10-31 | 2016-04-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
JP2012508238A (ja) * | 2008-11-07 | 2012-04-05 | ハー・ルンドベック・アクチエゼルスカベット | 生物活性を有するアミド |
US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
BR122021002201A8 (pt) | 2011-02-25 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
CA2873075A1 (en) * | 2012-05-11 | 2013-07-14 | Abbvie Inc. | Nampt inhibitors |
JP2015520752A (ja) | 2012-05-11 | 2015-07-23 | アッヴィ・インコーポレイテッド | Nampt阻害薬としてのピリダジンおよびピリジン誘導体 |
US9296723B2 (en) | 2012-05-11 | 2016-03-29 | Abbvie Inc. | NAMPT inhibitors |
KR20150036245A (ko) | 2012-08-02 | 2015-04-07 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 트리시클릭 화합물 |
MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
RU2019114228A (ru) | 2016-10-14 | 2020-11-16 | Тес Фарма С.Р.Л. | ИНГИБИТОРЫ ДЕКАРБОКСИЛАЗЫ ПОЛУАЛЬДЕГИДА α-АМИНО-β-КАРБОКСИМУКОНОВОЙ КИСЛОТЫ |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
AU2019385644A1 (en) | 2018-11-20 | 2021-06-03 | Tes Pharma S.R.L. | Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase |
TW202045476A (zh) | 2019-02-13 | 2020-12-16 | 美商默沙東藥廠 | 5-烷基吡咯啶食慾素受體促效劑 |
CN111825689B (zh) * | 2019-04-17 | 2023-05-05 | 中国医药研究开发中心有限公司 | 一种二氢吡唑啉酮类化合物的晶型及其制备方法 |
WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
KR20230053639A (ko) | 2020-08-18 | 2023-04-21 | 머크 샤프 앤드 돔 엘엘씨 | 비시클로헵탄 피롤리딘 오렉신 수용체 효능제 |
EP4374698A1 (en) | 2022-11-28 | 2024-05-29 | The Procter & Gamble Company | Pyridinium esters |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4111850A (en) * | 1977-02-16 | 1978-09-05 | Amp Incorporated | Organic photoconductors and methods |
FR2546163B1 (fr) * | 1983-05-16 | 1987-10-09 | Centre Nat Rech Scient | Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application |
JPS6079348A (ja) | 1983-10-06 | 1985-05-07 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
GB8524157D0 (en) * | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
US5234942A (en) * | 1984-10-19 | 1993-08-10 | Ici Americas Inc. | Heterocyclic amides and leucotriene antagonistic use thereof |
JPH0831980B2 (ja) | 1987-12-28 | 1996-03-27 | 松下電器産業株式会社 | 映像信号処理装置 |
US4965284A (en) * | 1988-05-19 | 1990-10-23 | American Cyanamid Company | Substituted dibenzothiophenes |
EP0342433A3 (en) | 1988-05-19 | 1991-06-19 | American Cyanamid Company | Substituted dibenzothiaphenes |
EP0381422B1 (en) | 1989-02-02 | 1996-10-23 | Yamanouchi Pharmaceutical Co. Ltd. | Tetrahydrobenzimidazole derivatives |
US5254135A (en) * | 1989-10-20 | 1993-10-19 | L'oreal | Methods for dyeing keratinous fibres with aminoindoles, compositions and devices for use |
IE913204A1 (en) | 1990-09-13 | 1992-02-25 | Beecham Group Plc | Novel compounds |
ES2114569T3 (es) | 1991-10-16 | 1998-06-01 | Richardson Vicks Inc | Sistema mejorado de penetracion en la piel para la administracion topica mejorada de farmacos. |
EG20380A (en) | 1991-10-16 | 1999-02-28 | Richardson Vicks Inc | Enhanced skin penetration system for improved topical delivery of drugs |
GB9203637D0 (en) | 1992-02-19 | 1992-04-08 | Smithkline Beecham Plc | Novel treatment |
WO1993018026A1 (en) | 1992-03-04 | 1993-09-16 | Beecham Group Plc | Indole ureas as 5-ht1c receptor antogonists |
GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
WO1996010571A1 (en) | 1994-09-30 | 1996-04-11 | Pfizer Inc. | 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[1,2-a]PYRAZINE DERIVATIVES |
US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
WO1997019682A1 (en) | 1995-12-01 | 1997-06-05 | Synaptic Pharmaceutical Corporation | Aryl sulfonamide and sulfamide derivatives and uses thereof |
AU7692696A (en) * | 1995-12-01 | 1997-06-27 | Novartis Ag | Heteroaryl derivatives |
CN1083831C (zh) * | 1996-01-10 | 2002-05-01 | 旭化成株式会社 | 新的三环化合物及含有它们的药物组合物 |
AU734710B2 (en) | 1996-07-08 | 2001-06-21 | Kyowa Hakko Kirin Co., Ltd. | Calcium receptor active compounds |
JP3679207B2 (ja) | 1996-09-12 | 2005-08-03 | 富士写真フイルム株式会社 | ハロゲン化銀写真感光材料 |
AU5410498A (en) | 1996-12-12 | 1998-07-03 | Banyu Pharmaceutical Co., Ltd. | Pyrazole derivatives |
AU6267198A (en) | 1997-02-14 | 1998-09-08 | Bayer Corporation | Amides as npy5 receptor antagonists |
WO1998035957A1 (en) | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
CA2282390A1 (en) | 1997-04-17 | 1998-10-22 | Yukio Fujisawa | Thermogenic composition and benzazepine thermogenics |
FR2763942B1 (fr) | 1997-06-02 | 2002-09-13 | Asepta Sa Lab | Nouveau procede de preparation de n-acylaminoacides |
AU735249B2 (en) | 1997-07-03 | 2001-07-05 | Asahi Kasei Kabushiki Kaisha | Novel tricyclic compounds having saturated rings and medicinal compositions containing the same |
DE19730847A1 (de) | 1997-07-18 | 1999-01-28 | Bayer Ag | Tricyclisch substituierte Oxazolidinone |
JPH1174077A (ja) | 1997-08-28 | 1999-03-16 | Junji Kido | ビニル系重合体を用いた積層型エレクトロルミネッセンス素子 |
JPH11130817A (ja) | 1997-08-28 | 1999-05-18 | Junji Kido | ビニル系重合体及びそれを用いたエレクトロルミネッセンス素子 |
CN101328186A (zh) * | 1997-11-11 | 2008-12-24 | 辉瑞产品公司 | 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物 |
DE19753522A1 (de) | 1997-12-03 | 1999-06-10 | Boehringer Ingelheim Pharma | Substituierte Indole, ihre Herstellung und ihre Verwendung als Arzneimittel |
SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
WO1999032111A1 (en) | 1997-12-22 | 1999-07-01 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS |
PT1042305E (pt) | 1997-12-22 | 2005-10-31 | Bayer Pharmaceuticals Corp | Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas |
US6063934A (en) | 1998-03-25 | 2000-05-16 | Bristol-Myers Squibb Company | Imidazolone anorectic agents: 1. 2-substituted-3,5-dihydro-5,5-diphenyl-4H-imidazol-4-ones |
WO1999048868A2 (en) | 1998-03-26 | 1999-09-30 | Sugen, Inc. | Heterocyclic classes of compounds for the modulating tyrosine protein kinase |
CA2326606A1 (en) | 1998-04-02 | 1999-10-14 | Neurogen Corporation | Aminoalkyl substituted 9h-pyridino[2,3-b]indole and 9h-pyrimidino[4,5-b]indole derivatives:crf1 and npy1 receptors |
US6221875B1 (en) | 1998-04-02 | 2001-04-24 | Neurogen Corporation | Substituted 9H-pyridino [2,3-B]indole and 9H-pyrimidino [4,5-B]indole derivatives: selective neuropeptide Y receptor ligands |
AUPP285898A0 (en) | 1998-04-07 | 1998-04-30 | Fujisawa Pharmaceutical Co., Ltd. | Amido derivatives |
JP2004503462A (ja) | 1998-04-29 | 2004-02-05 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 肥満症及び他の障害の処置において有用な神経ペプチドyy5レセプターのためのリガンドとしてのn−置換アミノテトラリン |
PE20000564A1 (es) | 1998-06-08 | 2000-07-05 | Schering Corp | Antagonistas receptores y5 de neuropeptidos |
JP4511042B2 (ja) | 1998-08-07 | 2010-07-28 | メルク セローノ ソシエテ アノニム | 不妊症の治療のためのfsh模倣物 |
NZ510988A (en) | 1998-10-07 | 2005-01-28 | Ortho Mcneil Pharm Inc | N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor |
WO2000023425A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
AU3840000A (en) | 1999-04-20 | 2000-11-02 | Meiji Seika Kaisha Ltd. | Tricyclic compounds |
EP1177188B1 (en) | 1999-05-12 | 2005-10-12 | Ortho-McNeil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
WO2001007409A1 (en) | 1999-07-23 | 2001-02-01 | Astrazeneca Uk Limited | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
GB0011013D0 (en) | 2000-05-09 | 2000-06-28 | Astrazeneca Ab | Chemical compounds |
WO2001090120A2 (en) | 2000-05-19 | 2001-11-29 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the evx1 gene |
US20040067999A1 (en) | 2000-12-22 | 2004-04-08 | Block Michael Howard | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
GB0121941D0 (en) | 2001-09-11 | 2001-10-31 | Astrazeneca Ab | Chemical compounds |
-
2000
- 2000-05-05 GB GBGB0010757.3A patent/GB0010757D0/en not_active Ceased
-
2001
- 2001-05-01 NZ NZ522188A patent/NZ522188A/en unknown
- 2001-05-01 JP JP2001582315A patent/JP2003532723A/ja active Pending
- 2001-05-01 EP EP01925687A patent/EP1278739A1/en not_active Withdrawn
- 2001-05-01 MX MXPA02010563A patent/MXPA02010563A/es unknown
- 2001-05-01 BR BR0110548-5A patent/BR0110548A/pt not_active IP Right Cessation
- 2001-05-01 IL IL15223001A patent/IL152230A0/xx unknown
- 2001-05-01 AU AU2001252372A patent/AU2001252372A1/en not_active Abandoned
- 2001-05-01 US US10/275,529 patent/US6967216B2/en not_active Expired - Fee Related
- 2001-05-01 CN CN01812237A patent/CN1440401A/zh active Pending
- 2001-05-01 KR KR1020027014772A patent/KR20020093975A/ko not_active Application Discontinuation
- 2001-05-01 CA CA002406634A patent/CA2406634A1/en not_active Abandoned
- 2001-05-01 WO PCT/GB2001/001899 patent/WO2001085714A1/en active IP Right Grant
- 2001-05-04 AR ARP010102135A patent/AR028414A1/es not_active Application Discontinuation
-
2002
- 2002-10-25 ZA ZA200208674A patent/ZA200208674B/en unknown
- 2002-11-04 NO NO20025286A patent/NO20025286D0/no not_active Application Discontinuation
-
2005
- 2005-05-12 US US11/127,582 patent/US7332492B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2003532723A (ja) | 2003-11-05 |
ZA200208674B (en) | 2004-02-10 |
IL152230A0 (en) | 2003-05-29 |
WO2001085714A1 (en) | 2001-11-15 |
NZ522188A (en) | 2004-04-30 |
AU2001252372A1 (en) | 2001-11-20 |
US20050209233A1 (en) | 2005-09-22 |
CA2406634A1 (en) | 2001-11-15 |
US20030225097A1 (en) | 2003-12-04 |
NO20025286L (no) | 2002-11-04 |
US6967216B2 (en) | 2005-11-22 |
AR028414A1 (es) | 2003-05-07 |
MXPA02010563A (es) | 2003-03-10 |
KR20020093975A (ko) | 2002-12-16 |
CN1440401A (zh) | 2003-09-03 |
GB0010757D0 (en) | 2000-06-28 |
NO20025286D0 (no) | 2002-11-04 |
US7332492B2 (en) | 2008-02-19 |
EP1278739A1 (en) | 2003-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0110548A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, método de tratamento de distúrbios mediados pelo receptor de neuropeptìdio y5 em um animal de sangue quente, método de tratamento de distúrbios da alimentação em um animal de sangue quente, método para promover perda de peso em um animal de sangue quente, e, uso de um composto ou de um seu sal, prodroga ou solvato farmacêuticamente aceitável | |
BR0212484A (pt) | Composto, processo para a preparação e uso do mesmo, método de tratamento de distúrbios alimentares em um animal de sangue quente, e, composição farmacêutica | |
BRPI0215312B8 (pt) | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
BR9916590A (pt) | Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, método para a produção de um efeito anti-câncer em um animal de sangue quente, uso do derivado de pirimidina, e, composição farmacêutica | |
BR0108600A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória | |
EA199901014A1 (ru) | C-4"-замещенные макролидные производные | |
BRPI0516093A (pt) | derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente | |
BR9911482A (pt) | Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto | |
BR0116388A (pt) | Composto, processo para preparar um composto, composição farmacêutica e método para tratar, em um animal de sangue quente, distúrbios de alimentação e uso de um composto | |
BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
BR9714082A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto. | |
BR0109828A (pt) | Composto, processo para a prepapação do mesmo ou de um sal deste, composição farmacêutica, uso do composto ou de um sal deste farmaceuticamente aceitável, e, método para a produção de um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente em necessidade de tal tratamento | |
BRPI0519398A2 (pt) | compostos de piridina para o tratamento de doenÇas mediadas por prostaglandina | |
BR0317524A (pt) | Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso | |
BRPI0416605A (pt) | composto, processo para preparar um composto, uso de um composto, métodos de inibição da atividade de trk, de tratamento ou profilaxia de cáncer, e de produção de um efeito anti-proliferativo em um animal de sangue quente e composição farmacêutica | |
BR0113176A (pt) | Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos | |
BRPI0416004A (pt) | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo | |
BR0015420A (pt) | Composto, composição farmacêutica, métodos de tratamento de uma doença ou de um distúrbio associados com agonismo patogênio, para a localização de receptores gabaa, em uma amostra de tecido, de inibição da ligação de um composto de benzodiazepina em um receptor gabaa, e de alteração da atividade de transdução de sinal de receptores gabaa, agonismo inverso ou antagonismo do receptor gabaa, uso de um composto, e , composição faramcêutica embalada | |
BR0114321A (pt) | Composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para preparar um composto | |
WO2003048164A3 (en) | Adenosine a2a receptor antagonists | |
CA2468649A1 (en) | Adenosine a2a receptor antagonists | |
BR0313880A (pt) | composto, pró-droga, composição farmacêutica, composição e método para modular receptor de cálcio, método para prevenir ou tratar doenças ósseas, e, uso do composto ou um sal deste ou uma pró-droga deste | |
BR0109109A (pt) | Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos | |
BR0012764A (pt) | Composto, processo para preparar um composto, composição farmacêutica, uso de um composto e método de tratar um paciente humano ou animal | |
BR0316690A (pt) | Composto, prodroga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto, composição farmacêutica, e processo para a preparação de um composto |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009. |